JERSEY CITY, N.J., May 28, 2015 – TrialScope, the global leader in clinical trial transparency and compliance solutions, today announced that it is adding another clinical trial sponsor to its growing client list for the PharmaCM clinical trial disclosure platform. The latest sponsor to join TrialScope’s client list selected the PharmaCM platform to replace an existing commercial product that had been previously implemented.
The new account represents continued growth for TrialScope since the company acquired the PharmaCM platform in June 2014. Currently, over 8,000 users around the world are managing almost 30,000 clinical trial registrations using the PharmaCM platform.
Mike Forgash, CEO, TrialScope, commented, “The TrialScope team looks forward to working with a new sponsor team and adding to its growing roster of satisfied clients. Our expanding customer base is a testament to the simplicity, efficiency and overall value that our zero-footprint solutions bring to complex clinical trial disclosure processes. Our team’s strong reputation for depth of knowledge and breadth of experience is attractive to clients of all sizes who are looking to stay ahead of the curve regarding ever-changing global regulatory requirements and need a disclosure-driven solution as opposed to simply a technology. This is especially important as emerging regulations (such as the EU Clinical Trials Regulation) add complexity to global trial disclosure processes.”
Thomas Wicks, Chief Strategy Officer, noted that the TrialScope team is leveraging its “Rapid Path to Compliance,” a proven engagement methodology based on collaboration and compliance and focused on quickly implementing the PharmaCM platform and decreasing the client’s time to productivity. He added, “As new clients come aboard, we have a unique chance to partner with them to transform their business practices and lower risks of non-compliance. Our practical knowledge is baked into our Rapid Path to Compliance methodology so clients get the combined benefits of our experience and our technology platform to simplify compliance and increase productivity.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.